Chlamydia pneumoniae Growth Inhibition in Cells by the Steroid Receptor Antagonist RU486 (Mifepristone)

Antimicrobial Agents and Chemotherapy
2008.0

Abstract

Since steroids are powerful anti-inflammatory agents and increase susceptibility to a variety of infections, including Chlamydia (Chlamydophila) pneumoniae respiratory tract infections, the effect of the steroid receptor antagonist RU486 (mifepristone) on C. pneumoniae growth in epithelial HEp-2 cells was examined. Treatment of HEp-2 cells with RU486 significantly inhibited the growth of C. pneumoniae in a dose-dependent manner. Electron microscopic studies also revealed that the treatment of infected cells with RU486 resulted in a marked destruction of infecting organisms. The addition of the host cell protein synthesis inhibitor cycloheximide to the infected cells did not alter the inhibition of C. pneumoniae growth by RU486. Pretreatment of C. pneumoniae organisms with RU486 before addition to culture also did not result in any modulation of bacterial growth in the cells. However, the binding of RU486 to C. pneumoniae organisms in cells at 24 h after infection was demonstrated by immune electron microscopy with anti-RU486 antibody. Incubation of cells with anti-RU486 antibody completely diminished the inhibition of C. pneumoniae growth by RU486. These results indicate that RU486 may directly bind to the bacteria within cells and cause the destruction of C. pneumoniae. This novel mode of regulation of C. pneumoniae growth in cells by RU486 might provide a new approach to understanding complicated aspects of C. pneumoniae infection.

Knowledge Graph

Similar Paper

Chlamydia pneumoniae Growth Inhibition in Cells by the Steroid Receptor Antagonist RU486 (Mifepristone)
Antimicrobial Agents and Chemotherapy 2008.0
The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P‐glycoprotein function
FEBS Letters 1994.0
Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against Chlamydia pneumoniae
Journal of Medicinal Chemistry 2010.0
Reversal of MRP-Mediated Multidrug Resistance in Human Lung Cancer Cells by the Antiprogestatin Drug RU486
Biochemical and Biophysical Research Communications 1999.0
In Vitro Activity of CEM-101, a New Fluoroketolide Antibiotic, against Chlamydia trachomatis and Chlamydia ( Chlamydophila ) pneumoniae
Antimicrobial Agents and Chemotherapy 2010.0
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy
Journal of Natural Products 2017.0
Rifampin Inhibits Prostaglandin E<sub>2</sub>Production and Arachidonic Acid Release in Human Alveolar Epithelial Cells
Antimicrobial Agents and Chemotherapy 2007.0
Synthesis and Antichlamydial Activity of Molecules Based on Dysregulators of Cylindrical Proteases
Journal of Medicinal Chemistry 2020.0
Roxithromycin Favorably Modifies the Initial Phase of Resistance against Infection with Macrolide-Resistant Streptococcus pneumoniae in a Murine Pneumonia Model
Antimicrobial Agents and Chemotherapy 2007.0
Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists
Bioorganic &amp; Medicinal Chemistry Letters 2004.0